CorMedix Raised Guidance in May, but That Was Before August Expectations Reset

CorMedix Inc (CRMD) reports second-quarter 2026 earnings tomorrow, August 13, with analysts expecting $0.26 per share — a notable decline from the $0.28 reported in the same quarter last year. The central question is whether the company can reverse a troubling trend of downward estimate revisions that has seen full-year 2026 expectations collapse from $1.82 to just $0.51, while the stock trades at $7.10 amid deteriorating technical momentum and a strengthening sell signal.

Part 1: Earnings Preview

CorMedix Inc is a pharmaceutical company focused on developing and commercializing therapeutic products for critical care and chronic dialysis patients, with its lead product DefenCath targeting catheter-related bloodstream infections. The company reports before market open on August 13, 2026, with the consensus estimate calling for $0.26 per share for the quarter ending June 2026. Most recently, CRMD reported $0.43 per share for the March 2026 quarter, beating estimates by 22.86%.

Year-over-year, the outlook has deteriorated significantly. The $0.26 consensus represents a 7.14% decline from the $0.28 reported in June 2025, marking a reversal from the strong growth trajectory the company demonstrated through much of 2025. More concerning is the dramatic compression in full-year expectations: fiscal 2026 estimates have plunged 71.98% from the prior year's $1.82 to just $0.51, while fiscal 2027 projections of $0.01 suggest analysts see minimal earnings power ahead.

Three key themes define this earnings story: Commercial Execution and Revenue Trajectory — investors will scrutinize DefenCath sales momentum and whether the company can demonstrate sustainable commercial traction after initial launch enthusiasm; Profitability Sustainability — the sharp estimate cuts raise questions about whether recent profitability was transitory or reflects a durable business model, particularly as the next quarter's consensus calls for a $0.08 loss; and Cash Burn and Runway — with estimates collapsing and the stock down significantly from highs, investors need clarity on the company's financial position and path to sustained profitability.

Analyst commentary ahead of the release reflects caution despite maintaining bullish ratings. The single analyst covering the quarter has revised estimates downward from $0.28 to $0.26 over the past 90 days, part of a broader pattern of deteriorating expectations across all time horizons. While the analyst community maintains a strong consensus with 4 Strong Buys and 2 Moderate Buys, the dramatic estimate cuts suggest growing uncertainty about the commercial outlook and profitability trajectory.

Part 2: Historical Earnings Performance

CorMedix has demonstrated a volatile but generally positive earnings surprise pattern over the past four quarters, though recent performance shows signs of inconsistency. The company delivered strong beats in three of the past four quarters, with the June 2025 quarter showing a 40.00% surprise ($0.28 actual vs. $0.20 estimate), September 2025 posting an 18.75% beat ($0.57 vs. $0.48), and most recently March 2026 exceeding expectations by 22.86% ($0.43 vs. $0.35).

The notable exception was December 2025, when CRMD missed estimates by 29.07%, reporting $0.61 against a consensus of $0.86. This significant miss appears to have triggered the wave of estimate revisions that has compressed full-year expectations so dramatically. The pattern suggests the company's earnings remain difficult to forecast, with actual results swinging from substantial beats to meaningful misses.

The absolute EPS levels also tell a story of deceleration. After peaking at $0.61 in December 2025, reported earnings declined to $0.43 in March 2026, and the current quarter's $0.26 estimate would represent a further step-down. This trajectory, combined with the next quarter's projected loss of $0.08, raises questions about whether the profitability demonstrated in 2025 can be sustained or whether the business faces structural margin pressures as it scales.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CorMedix reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price behavior around CRMD earnings reveals extreme volatility, with an average absolute Day 0 move of 17.12% and an average Day 0 range of 18.83% — among the highest volatility profiles in the market. The stock has demonstrated dramatic swings in both directions, from a 31.85% decline in March 2025 to a 30.16% surge in August 2024, making earnings events high-risk, high-reward catalysts.

The pattern shows no clear directional bias, with four positive and four negative Day 0 reactions over the past eight quarters. However, the magnitude of moves has been consistently large, with six of eight quarters producing double-digit percentage swings. Day +1 follow-through has been more muted, averaging 2.91% with a 7.76% range, suggesting most of the price discovery occurs in the immediate reaction session.

Most recently, the May 2026 earnings produced a 5.73% gain on Day 0 with a 14.40% intraday range, followed by a 4.79% decline the next day — a pattern of initial optimism giving way to profit-taking. Given the deteriorating estimate trend and cautious technical setup heading into this release, investors should prepare for significant volatility in either direction.

Part 2.2: Options Market Expected Move

The options market is pricing a 13.17% expected move for the upcoming earnings release, implying a range between $6.17 and $8.04. This expected move is notably lower than CRMD's historical average earnings move of 17.12%, suggesting options traders may be underpricing the potential volatility based on the stock's track record of extreme post-earnings swings.

Part 3: What Analysts Are Saying

Analyst sentiment remains constructive despite the dramatic estimate cuts, with the consensus rating at 4.43 out of 5 — firmly in Strong Buy territory. The breakdown shows 4 Strong Buys, 2 Moderate Buys, and 1 Hold, with no sell ratings among the 7 analysts covering the stock. This bullish stance has remained unchanged over the past month, indicating analysts are maintaining conviction despite the deteriorating earnings outlook.

The average price target of $13.86 implies substantial 95% upside from the current price of $7.10, with estimates ranging from a low of $9.00 (27% upside) to a high of $19.00 (168% upside). This wide target range reflects significant uncertainty about the company's valuation, though even the most conservative target suggests meaningful appreciation potential.

However, the stability in ratings masks a more troubling trend in estimates. Over the past 90 days, the current quarter consensus has declined from $0.28 to $0.26, next quarter estimates have collapsed from $0.09 to a projected loss of $0.08, and full-year 2026 expectations have fallen from $1.06 to $0.51. This pattern of persistent downward revisions suggests analysts are struggling to model the business trajectory, even as they maintain buy ratings — a disconnect that often precedes rating downgrades if operational performance continues to disappoint.

Part 4: Technical Picture

The technical picture has deteriorated significantly heading into earnings, with the Barchart Technical Opinion showing a 72% Sell signal — a sharp weakening from the 16% Buy signal just one month ago and the 56% Sell reading last week. This rapid shift reflects mounting downside momentum as the stock has broken below key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates near-term momentum is decisively negative, suggesting immediate pressure heading into the earnings release
• Medium-term (Hold): Neutral reading suggests the intermediate trend remains in balance despite short-term weakness
• Long-term (100% Sell): Strong sell signal reflects significant deterioration in the longer-term trend structure

Trend Characteristics: The sell signal is characterized as Soft in strength but Strengthening in direction, indicating downside momentum is building but has not yet reached extreme oversold levels that might suggest an imminent reversal.

The moving average structure confirms the bearish setup, with CRMD trading at $7.10 — below all major moving averages. The stock sits below the 5-day ($7.38), 10-day ($7.44), 20-day ($7.65), 50-day ($8.15), 100-day ($7.81), and 200-day ($8.50) averages, indicating consistent selling pressure across all timeframes.

Key technical levels to watch include the 200-day moving average at $8.50, which has served as resistance and now sits 19.7% above the current price, and the 50-day average at $8.15, which represents the first major overhead resistance level. On the downside, the stock is testing recent lows with limited technical support visible. The overall setup is cautionary for earnings, with the stock in a confirmed downtrend, all moving averages in bearish alignment, and momentum indicators flashing sell signals across multiple timeframes. The combination of deteriorating technicals and collapsing earnings estimates creates a challenging backdrop, though the extreme analyst price targets suggest potential for a sharp reversal if the company can deliver positive surprises on both results and forward guidance.